CYP2B7P was found to be a target gene of hsa-miR-122 that is a diagnostic biomarker of HCC as well as of non-alcoholic fatty liver disease (NAFLD) [25]. Here, CYP2B7P is linked to metabolic dysfunction-associated steatotic liver disease.